---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-229089"
form_type: "8-K"
ticker: "SLN"
cik: "0001479615"
company_name: "Silence Therapeutics plc"
filed_at: "2026-05-18T21:00:15+00:00"
generated_at: "2026-05-18T21:09:26.582558+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Silence Therapeutics enters new ATM with Jefferies; says not PFIC for 2025

## Summary
- Entered at-the-market equity offering agreement with Jefferies LLC; prior 2021 ATM agreement terminated.
- Jefferies receives 3.0% commission on gross proceeds; no minimum obligation to sell ADSs.
- After further tax analysis, company believes it was not a PFIC for FY 2025 (previously disclosed potential PFIC status).
- Added risk factor noting PFIC classification is fact-intensive and could change; no assurance from IRS.
- Legal opinion from Cooley (UK) LLP on ADS validity filed as exhibit 5.1.

## SEC filing metadata
- accession: 0001193125-26-229089
- form_type: 8-K
- ticker: SLN
- cik: 0001479615
- company_name: Silence Therapeutics plc
- filed_at: 2026-05-18T21:00:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 1.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1479615/000119312526229089/0001193125-26-229089-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1479615/000119312526229089/sln-20260518.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-229089
- JSON: https://secwatch.observer/filing/0001193125-26-229089.json
- Plain text: https://secwatch.observer/filing/0001193125-26-229089.txt

## Key facts
- Material Agreements
  Silence Therapeutics plc terminated Prior Sales Agreement with Jefferies LLC (effective 2026-05-18).
  - Action: termination
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Effective: 2026-05-18
  source text: The Sales Agreement replaces the prior Open Market Sale Agreement SM , dated October 15, 2021, by and between the Company and Jefferies (the “Prior Sales Agreement’), which was terminated as of May 18, 2026 pursuant to the terms of the Sales Agreement.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526229089/0001193125-26-229089-index.htm
- Material Agreements
  Silence Therapeutics plc entered into Sales Agreement with Jefferies LLC valued at aggregate offering amount not exceeding the Maximum Program Amount (effective 2026-05-18).
  - Action: entry
  - Agreement: atm program
  - Counterparty: Jefferies LLC
  - Value: aggregate offering amount not exceeding the Maximum Program Amount
  - Effective: 2026-05-18
  source text: On May 18, 2026, Silence Therapeutics plc (the “Company” or “we”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1479615/000119312526229089/0001193125-26-229089-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.